Table 1.

Baseline characteristics of the patients, the oncological disease, the AKI presentation and outcome

Patient number	Age/gender/ race	Comorbidities	Malignancy	Type of CPI and duration	Baseline serum creatinine (mg/dL)	Cancer outcome	Non-renal irAEs
1	59/F/C	GERD	Lung	Anti-CTLA-4 and anti PD-L1 (four cycles)	0.7	PD	No
2	67/F/C	GERD	Pancreas	Anti-PD-L1 and MEK inhibitor (two cycles)	0.8	PD	No (fever)
3	83/F/C	HT, dyslipidaemia	Melanoma	Anti-PD-1 and anti-LAG-3 antibody (three cycles)	0.7	CR	Arthralgia
4	85/M/C	DM, HT, dyslipidaemia, GERD, CKD	Lung	Anti-PD-1 and anti-cMET antibody (seven cycles)	1.3	PD	No
5	68/F/C	HT, GERD	Lung	Anti-PD-1 (three cycles)	1.1	SD	No
6	63/M/C	GERD	Lung	Anti-PD-L1 (one cycle)	0.9	PR	Arthralgia
7	75/M/C	GERD, HT	Melanoma	Anti-PD-1 and EGFR inhibitor (one cycle)	0.9	CR	Esophagitis
8	61/M/C	–	Lung	Anti-PD-1 and RAS inhibitor (five cycles)	0.9	PD	No

CR, complete response; GERD, Gastroesophageal reflux disease; HT, Hypertension; MEK, mitogen-activated protein; PD, partial disease; PR, partial response; SD, stable disease.